Tags

Type your tag names separated by a space and hit enter

Somatostatin and the endocrine pancreas.
Curr Top Mol Endocrinol. 1976; 3:127-43.CT

Abstract

Thus far, somatostatin has been used primarily as a research tool to investigate pancreatic alpha- and beta- cell function. On the basis of its ability to inhibit insulin and glucagon secretion, several therapeutic applications have been suggested: e.g., as an adjunct in the treatment of diabetes mellitus, or as a palliative agent in inoperable islet tumors. Current experiments are underway to develop more specific analogs with longer durations of action to permit clinical evaluation of these potential applications. The presence of somatostatin within the pancreatic D cells raises the possibility that it may function as a local regulator of insulin and glucagon release. Clearly, further work is needed to delineate the factors governing the secretion of somatostatin and its mode of action. Such studies may uncover a new class of syndromes resulting from D-cell dysfunction.

Authors

Gerich JE
No affiliation info available

MeSH

Adenoma, Islet CellAnimalsBlood GlucoseDiabetes MellitusFatty Acids, NonesterifiedGlucagonHumansHydroxybutyratesHyperglycemiaInsulinInsulin SecretionIslets of LangerhansSomatostatin

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

211005

Citation

Gerich, J E.. "Somatostatin and the Endocrine Pancreas." Current Topics in Molecular Endocrinology, vol. 3, 1976, pp. 127-43.
Gerich JE. Somatostatin and the endocrine pancreas. Curr Top Mol Endocrinol. 1976;3:127-43.
Gerich, J. E. (1976). Somatostatin and the endocrine pancreas. Current Topics in Molecular Endocrinology, 3, 127-43.
Gerich JE. Somatostatin and the Endocrine Pancreas. Curr Top Mol Endocrinol. 1976;3:127-43. PubMed PMID: 211005.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Somatostatin and the endocrine pancreas. A1 - Gerich,J E, PY - 1976/1/1/pubmed PY - 1976/1/1/medline PY - 1976/1/1/entrez SP - 127 EP - 43 JF - Current topics in molecular endocrinology JO - Curr Top Mol Endocrinol VL - 3 N2 - Thus far, somatostatin has been used primarily as a research tool to investigate pancreatic alpha- and beta- cell function. On the basis of its ability to inhibit insulin and glucagon secretion, several therapeutic applications have been suggested: e.g., as an adjunct in the treatment of diabetes mellitus, or as a palliative agent in inoperable islet tumors. Current experiments are underway to develop more specific analogs with longer durations of action to permit clinical evaluation of these potential applications. The presence of somatostatin within the pancreatic D cells raises the possibility that it may function as a local regulator of insulin and glucagon release. Clearly, further work is needed to delineate the factors governing the secretion of somatostatin and its mode of action. Such studies may uncover a new class of syndromes resulting from D-cell dysfunction. SN - 0094-6761 UR - https://www.unboundmedicine.com/medline/citation/211005/Somatostatin_and_the_endocrine_pancreas_ DB - PRIME DP - Unbound Medicine ER -